Nat Med:新研究为肺疾病治疗提供参考依据

2015-07-29 佚名 中国科学报

近日,中科院上海生科院营养科学所研究员周斌研究组在最新研究中,利用遗传谱系示踪技术,揭示了c-kit+干细胞在肺的生理稳态和损伤修复过程中的作用。相关研究成果已在线发表于《自然—医学》。c-kit+细胞被认为是心脏和肺损伤修复过程中的干细胞来源,近几年的实验研究证明该细胞具有多能性,能够分化成心脏和肺中的多种细胞类型。但是这些结论都基于细胞体外培养以及移植实验,缺乏在体实验的验证。研究人员用小鼠进

近日,中科院上海生科院营养科学所研究员周斌研究组在最新研究中,利用遗传谱系示踪技术,揭示了c-kit+干细胞在肺的生理稳态和损伤修复过程中的作用。相关研究成果已在线发表于《自然—医学》。


c-kit+细胞被认为是心脏和肺损伤修复过程中的干细胞来源,近几年的实验研究证明该细胞具有多能性,能够分化成心脏和肺中的多种细胞类型。但是这些结论都基于细胞体外培养以及移植实验,缺乏在体实验的验证。


研究人员用小鼠进行遗传谱系示踪,然后在肺的生理稳态和冰冻损伤以及肺切除的损伤修复过程中追踪c-kit+细胞的命运。研究结果发现,不论是在正常组织还是损伤修复过程中,绝大多数c-kit+细胞参与肺组织血管的形成,转分化为血管内皮细胞,且在损伤过程中增殖,参与损伤后的血管新生,促进肺的修复过程。


值得一提的是,研究过程中利用遗传谱系示踪技术并没有检测到c-kit+细胞产生任何的上皮细胞类型,这与Kajstura等在2011年《新英格兰医学杂志》上发表的研究相悖。


周斌表示,该项研究通过实验质疑了c-kit+干细胞转分化成为肺上皮细胞谱系的结论正确性,并为c-kit+干细胞是否能临床转化治疗肺疾病提供了初步参考依据。


原始出处:


Liu Q, Huang X, Zhang H, Tian X, He L, Yang R, Yan Y, Wang QD, Gillich A, Zhou B.c-kit+ cells adopt vascular endothelial but not epithelial cell fates during lung maintenance and repair.Nat Med. 2015 Jul 13.


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1880753, encodeId=e0901880e5356, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 26 19:17:00 CST 2016, time=2016-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982747, encodeId=384d1982e4720, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Wed Feb 03 12:17:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35138, encodeId=942a35138ff, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:19:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606557, encodeId=661e160655e68, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 31 02:17:00 CST 2015, time=2015-07-31, status=1, ipAttribution=)]
    2016-05-26 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1880753, encodeId=e0901880e5356, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 26 19:17:00 CST 2016, time=2016-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982747, encodeId=384d1982e4720, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Wed Feb 03 12:17:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35138, encodeId=942a35138ff, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:19:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606557, encodeId=661e160655e68, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 31 02:17:00 CST 2015, time=2015-07-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1880753, encodeId=e0901880e5356, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 26 19:17:00 CST 2016, time=2016-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982747, encodeId=384d1982e4720, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Wed Feb 03 12:17:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35138, encodeId=942a35138ff, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:19:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606557, encodeId=661e160655e68, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 31 02:17:00 CST 2015, time=2015-07-31, status=1, ipAttribution=)]
    2015-08-06 hlycom3356

    期待有更多研究

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1880753, encodeId=e0901880e5356, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=9, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Thu May 26 19:17:00 CST 2016, time=2016-05-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982747, encodeId=384d1982e4720, content=<a href='/topic/show?id=89c4e06902e' target=_blank style='color:#2F92EE;'>#疾病治疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=10, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70690, encryptionId=89c4e06902e, topicName=疾病治疗)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d64f419, createdName=qindq, createdTime=Wed Feb 03 12:17:00 CST 2016, time=2016-02-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=35138, encodeId=942a35138ff, content=期待有更多研究, beContent=null, objectType=article, channel=null, level=null, likeNumber=94, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=332823945, createdName=hlycom3356, createdTime=Thu Aug 06 23:19:00 CST 2015, time=2015-08-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1606557, encodeId=661e160655e68, content=<a href='/topic/show?id=eb6b1145939' target=_blank style='color:#2F92EE;'>#Med#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=19, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=11459, encryptionId=eb6b1145939, topicName=Med)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=552a19396740, createdName=ms3994565386320060, createdTime=Fri Jul 31 02:17:00 CST 2015, time=2015-07-31, status=1, ipAttribution=)]

相关资讯

Eur Heart J:慢性阻塞性肺疾病患者心源性猝死风险增加(Rotterdam研究)

比利时,根特大学医院Lies Lahousse等人研究了慢性阻塞性肺病与心源性猝死之间的关联,其研究成果发表在4月份European heart journal期刊上。 目的:心源性猝死(SCD)和慢性阻塞性肺疾病(COPD)在中老年人中是常见的疾病。之前已有研究明确了普通人群中慢性阻塞性肺病和心血管疾病之间存在一定的关联,尤其是与心源性猝死之间的关联。本研究旨在调查普通人群中慢性阻塞性肺病

PiZZ纯合子相关肺疾病患者常见肝纤维化

  α1-抗胰蛋白酶缺乏症是人类最常见的遗传性疾病之一,该病患者容易出现肝脏和肺脏损害,其在基因表型表达方面的显著异质性,在文献中也已有很好的记载,但对于那些以肺部病变为主要表现的该病患者而言,其慢性肝病的患病率、严重程度、及其与肺部病变的相互关系等,则很少为人所知。   为了明确在PiZZ纯合子相关肺疾病患者中,严重的肝纤维化、以及肝硬化的发生率及其危险因素,来自英国剑桥Addenbroo

ALIMENT PHARM THERAP:肝移植对门脉高压引起的肺疾病有效

  近日,《营养药理学与治疗学(Alimentary Pharmacology & Therapeutics)》杂志的一篇论文指出,肝移植是肝肺综合征和门脉肺动脉高压患者的有效治疗措施。但有效的筛查、早期诊断、术前改善生理指标和精细的术后护理将确保病人有良好的转归。[Aliment Pharmacol Ther 2012:&nbs